Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer ; volume:7 ; number:1 ; day:29 ; month:3 ; year:2019 ; pages:1-14 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (29.3.2019), 1-14, 12.2019
- Creator
-
Griguolo, Gaia
Pascual, Tomás
Dieci, Maria Vittoria
Guarneri, Valentina
Prat, Aleix
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-019-0548-6
- URN
-
urn:nbn:de:101:1-2019042019412115910423
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Griguolo, Gaia
- Pascual, Tomás
- Dieci, Maria Vittoria
- Guarneri, Valentina
- Prat, Aleix
- SpringerLink (Online service)
Other Objects (12)
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases